Patents by Inventor Paul Sanberg
Paul Sanberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9593070Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: March 12, 2014Date of Patent: March 14, 2017Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Patent number: 9402870Abstract: Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble A? protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A?1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.Type: GrantFiled: February 16, 2010Date of Patent: August 2, 2016Assignee: University of South FloridaInventors: Jun Tan, Paul Sanberg
-
Publication number: 20140194525Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: Targacept, Inc.Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Patent number: 8574640Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.Type: GrantFiled: October 8, 2010Date of Patent: November 5, 2013Assignees: University of South Florida, The Department of Veterans Affairs, Natura Therapeutics, Inc.Inventors: Cyndy Davis Sanberg, Paula Bickford, Paul Sanberg, Jun Tan, R. Douglas Shytle
-
Patent number: 8309352Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.Type: GrantFiled: November 9, 2006Date of Patent: November 13, 2012Assignee: University of South FloridaInventors: Paul Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel D. Richard
-
Patent number: 8026283Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: January 4, 2010Date of Patent: September 27, 2011Assignee: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20110038963Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.Type: ApplicationFiled: October 8, 2010Publication date: February 17, 2011Inventors: Cyndy Davis Sanberg, Paul Sanberg, Paula Bickford, R. Douglas Shytle, Jun Tan
-
Publication number: 20110028565Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: September 21, 2010Publication date: February 3, 2011Applicant: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20100286282Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: January 4, 2010Publication date: November 11, 2010Applicant: Targacept, Inc.Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20100150882Abstract: Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble A? protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A?1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.Type: ApplicationFiled: February 16, 2010Publication date: June 17, 2010Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Jun Tan, Paul Sanberg
-
Publication number: 20090280198Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.Type: ApplicationFiled: October 23, 2008Publication date: November 12, 2009Inventors: Cyndy Davis Sanberg, Paul Sanberg, Paula Bickford, R. Douglas Shytle, Jun Tan
-
Patent number: 7442394Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VITABLUE® blueberry extract, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.Type: GrantFiled: May 2, 2006Date of Patent: October 28, 2008Assignee: University of South FloridaInventors: Cyndy Davis Sanberg, Paul Sanberg, Paula Bickford, R. Douglas Shytle, Jun Tan
-
Publication number: 20080206206Abstract: Bone marrow stromal cells (BMSC) differentiate into neuron-like phenotypes in vitro and in vivo, engrafted into normal or denervated rat striatum. The BMSC administered into the ventricle did not remain localized to the site of the graft, but migrated throughout the brain and integrated into specific brain regions in various architectonic patterns. The most orderly integration of BMSC was in the laminar distribution of cerebellar Purkinje cells, where the BMSC-derived cells took on the Purkinje phenotype. The BMSC exhibited site-dependent differentiation and expressed several neuronal markers including neuron-specific nuclear protein, tyrosine hydroxylase and calbindin. Treated BMSC implanted intrastriatally stayed in the cortex and the striatum, produced tyrosine hydroxylase which produces the dopamine needed in Parkinson's disease.Type: ApplicationFiled: December 12, 2007Publication date: August 28, 2008Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Juan Sanchez-Ramos, Shijie Song, William Janssen, Paul Sanberg, Thomas Freeman
-
Publication number: 20080089905Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of substances selected from blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3, Spirulina, AFA or effective combinations and derivatives of these. For example, a supplement comprising wild blueberry, green tea extract, carnosine, vitamin D3, and AFA-Omega (EtOH) or Spirulina and AFA-Omega (EtOH) exhibits a synergistic and unexpected association with substantially increased proliferation of bone marrow stem cells and CD34+. A therapeutic amount of a substance that is associated with a substantial increase in stem cells may be used to prevent and repair damaged tissues of the brain, due to stroke, the heart, due to coronary artery disease or a heart attack.Type: ApplicationFiled: June 1, 2007Publication date: April 17, 2008Inventors: Cyndy Davis Sanberg, Paula Bickford, Paul Sanberg, Jun Tan, R. Shytle, Jerry Anderson
-
Publication number: 20080085330Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of substances selected from blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3, Spirulina, AFA or effective combinations and derivatives of these. For example, a supplement comprising wild blueberry, green tea extract, carnosine, vitamin D3, and a Spirulina and/or an AFA-Omega (EtOH) exhibited a synergistic and unexpected association with substantially increased proliferation of bone marrow stem cells and CD34+. A therapeutic amount of a substance that is associated with a substantial increase in stem cells may be used to prevent and repair damages tissues of the brain, due to stroke, the heart, due to coronary artery disease or a heart attack.Type: ApplicationFiled: June 1, 2007Publication date: April 10, 2008Inventors: Cyndy Davis Sanberg, Paula Bickford, Paul Sanberg, Jun Tan, R. Shytle
-
Publication number: 20070237751Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.Type: ApplicationFiled: November 9, 2006Publication date: October 11, 2007Applicants: UNIVERSITY OF SOUTH FLORIDA, Saneron CCEL Therapeutics, Inc.Inventors: Paul Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel Richard
-
Patent number: 7160724Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.Type: GrantFiled: March 7, 2001Date of Patent: January 9, 2007Assignee: University of South FloridaInventors: Paul Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel D. Richard
-
Publication number: 20060276551Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: April 5, 2006Publication date: December 7, 2006Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie Silver
-
Publication number: 20060275512Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.Type: ApplicationFiled: May 2, 2006Publication date: December 7, 2006Inventors: Cyndy Davis Sanberg, Paul Sanberg, Paula Bickford, R. Shytle, Jun Tan
-
Patent number: 7101916Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: May 19, 2003Date of Patent: September 5, 2006Assignee: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver